Future University In Egypt (FUE)
Future University is one of most promising private universities in Egypt. Through excellence in teaching, research and service, Future University strives to provide a comprehensive, high-quality education that prepares our graduates to be future leaders.
mainLogo
Altagamoa Al Khames, Main centre of town, end of 90th Street
New Cairo
Egypt

Mona El Assal

Basic information

Name : Mona El Assal
Title: Professor of Pharmaceutics at Pharmaceutics and Pharmaceutical Technology department at FUE University
Google Schoolar Link
Personal Info: Dr. Mona Ebrahim. Professor of Pharmaceutics at Pharmaceutics and Pharmaceutical Technology department.She got her Master and Doctoral degree from Cairo University

Education

Certificate Major University Year
PhD 2005
Masters 2000
Bachelor 1984

Researches /Publications

Delineating Penetration Enhancer-Enriched Liquid Crystalline Nanostructures as Novel Platforms for Improved Ophthalmic Delivery.

Mona Ebrahim Abdel Tawab Ahmed Elassal

El-Gendy MA, Mansour M, Ishak RA, Mortada ND.

01/04/2020

Download PDF
Novel biocompatible essential oil-based lipid nanocapsules with antifungal properties.

Mona Ebrahim Abdel Tawab Ahmed Elassal

Hussein A, Abdel-Mottaleb MM, Sammour O.

01/04/2020

Download PDF
NANO-SPONGE NOVEL DRUG DELIVERY SYSTEM AS CARRIER OF ANTI-HYPERTENSIVE DRUG.

Mona Ebrahim Abdel Tawab Ahmed Elassal

01/10/2019

Download PDF
NANO-SPONGE NOVEL DRUG DELIVERY SYSTEM AS CARRIER OF ANTI-HYPERTENSIVE DRUG

Mona Ebrahim Abdel Tawab Ahmed Elassal

Mona Ibrahim El Assal

01/10/2019

ABSTRACT Objective: The study was designed to prepare Nano-sponge formulation loaded with nifedipine. Studying parameters which affecting the formulas in addition to pharmacokinetics and toxicity tests. Methods: Nine Nano-sponge formulations were prepared by the solvent evaporation technique. Different ratios of polymer ethylcellulose, COpolymers β-cyclodextrin and hydroxypropyl β-cyclodextrin in addition to solubilizing agent polyvinyl alcohol were used. Thermal analysis, X-ray powder diffraction (XRPD), shape and surface morphology, particle size, %production yield, %porosity, % swelling, and % drug entrapment efficiency of Nano-sponge were examined. Release kinetic also studied beside comparison of pharmacokinetic parameters of the optimum choice formula and marketed one in addition to Toxicological consideration. Results: Particle size in the range of 119.1 nm to 529 nm which were increased due to the increase in the concentration of polymer to the drug. Nano-sponge revealed porous, spherical nature. Increased in the drug/polymer molar ratios (1:1 to 1:3) may increase their % production yield ranged from 62.1% to 92.4%. The drug content of different formulations was in the range of 77.9% to 94.7%, and entrapment efficiency was in the range of 82.72 % to 96.63%. Drug released in controlled sustained pattern and followed Higuchi, s diffusion mechanism. Pharmacokinetic parameters of optimized formula showed significant higher maximum plasma drug concentration, area under plasma concentration-time curve, volume of distribution and mean residence time. Nano-sponge loaded drug proved biological safety at low concentrations. Conclusion: Nano-sponge drug delivery system has showed small Nano size, porous with controlled drug release and significant-high plasma drug concentration that improved solubility, drug bioavailability and proved safety. Keywords: Cyclodextrins, Polymeric drug delivery system, Controlled release, Nanotechnology, Preclinical pharmacokinetics, Cytotoxicit

Download PDF
CHITOSAN NANOPARTICLES AS DRUG DELIVERY SYSTEM FOR CEPHALEXIN AND ITS ANTIMICROBIAL ACTIVITY AGAINST MULTIIDRUG RESISTENT BACTERIA

Mona Ebrahim Abdel Tawab Ahmed Elassal

MONA IBRAHIM EL-ASSAL1*, NAGWAN GALAL EL MENOFY2

01/07/2019

ABSTRACT Objective: The evolution of antimicrobial resistance is a universal obstacle that necessities the innovation of more effective and safe antimicrobial alternatives with synergistic properties. The purpose of this study was to investigate the possible improvement of cephalexin antimicrobial treatments by loading into chitosan-based nanoparticles, then evaluate their antibacterial and antibiofilm activities as well as determination of its cytotoxicity. Methods: Chitosan nanoparticles (CSNPs) were prepared by ionic gelation method. Parameters were studied to optimize the particle size of CSNPs including pH, stirring rate, homogenization and ultra-sonication time. Size was measured by transmission electron microscope (TEM) and Zeta sizer, morphology seen by scanning electron microscope (SEM). Entrapment efficiency, drug loading and drug content were calculated. Stability of both plain and loaded chitosan Nano-carriers, Drug release and Kinetics also compatibilities were studied. Antimicrobial activity of CSNPs and cephalexin loaded CSNPs were evaluated against 4 Gram-positive and 4 Gram-negative standard and clinical isolates by microdilution method, also assessment of antibiofilm activity of both formulas was investigated against two biofilm producers clinical isolates by tube assay in addition to determination of their cytotoxicity by MTT(3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. Results: Chitosan nanoparticles and its loaded antibiotics proved compatible combination with small Zeta size, suitable Zeta potential, maximum EE% and drug-loading capacity, sustained controlled release properties followed diffusion kinetic model and six month stability studies. Cephalexin loaded CSNPs showed better antimicrobial activity than plain CSNPs. Synergistic effects were found against S. aureus (ATCC 25923), B. subtilis (ATCC 9372), S. epidermidis, E. faecalis, P. aeruginosa (ATCC 29853) in addition to two carbapenem resistant isolates k. pneumoniae and E. coli. Also cephalexin loaded CSNPs exhibited antibiofilm activity against E. faecalis clinical isolate. Even though, cephalexin loaded CSNPs exhibited significant antibacterial activity, it showed less toxicity against mammalian cells, it had IC50 equal to 231.893 and did not exhibit any cytotoxicity against the WI-38 fibroblast cells at concentration 23.4 Conclusion: Cephalexin loaded CSNPs possessed good stability and sustained release effect in addition to its antimicrobial, antibiofilm activities and reduced cytotoxicity

Download PDF
EFFECT OF MICROCAPSULES SOLID DISPERSION OF METFORMIN HCl ORAL ADMINISTERED FORMULATION ON HYPERGLYCEMIA IN RATS

Mona Ebrahim Abdel Tawab Ahmed Elassal

Mona I. El-Assal1*, Ahmed Abdel Bari2 and Mohamed Rafat3

01/09/2018

The present study is to examine In-vivo pharmacodynamics antidiabetic effect following oral administration of the selected optimized microcapsules in comparison with oral metformin solution. Solid dispersions microcapsules were prepared using solvent evaporation method which enclosed preparation of a uniform dispersion of Metformin HCl in (Hydroxy propyl methylcellulose k100, Ethyl cellulose, Eudragit RL PO, Eudragit RS PO and Compritol 888 ATO). A two-factor, General factorial statistical design was used to quantitate the effect of polymer type(X1) and drug: polymer ratio(X2) on the release profile. Where polymer type and drug: polymer ratio were selected as independent variables, while Y1 (cumulative drug release after 1 h) and Y2 (cumulative drug release in 3 h), Y3 (cumulative drug release in10 h),Y4 (angle of repose ) and Y5(Hausner ratio) were selected as dependent variables. A convenient statistical model was made and a significantly controlled release rate was exhibited. The solid dispersions were characterized for their in vitro- release rate. The oral administration of formulae (T20) which consists of metformin HCl and compritol 888 ATO) in drug/polymer ratio (1:4) was chosen as optimum formula resulted in a clear long lasting Statistically significant anti-hyperglycemic effect up to 12 h as compared to diabetic control Group and metformin HCl solution treated group. Factorial design suggested only one optimized combination of the polymer by which maximum desirability obtained. The oral administration of formulae (T20) resulted in a clear long lasting statistically significant anti-hyperglycemic effect.

Download PDF
Olmesartan medoxomil-loaded self-nanoemulsifying drug delivery systems: design, in-vitro characterization, and pharmacokinetic assessments in rabbits via LC–MS/MS

Mona Ebrahim Abdel Tawab Ahmed Elassal

M. Ibrahim Tadros and O. Naem El-Gazayerly

01/04/2018

Olmesartan medoxomil (OLM) is a lipophilic (log P = 4.31) antihypertensive drug suffering from limited oral bioavailability in humans (26%) due to its low aqueous solubility, uncontrolled enzymatic conversion to the active metabolite (Olmesartan; OL) and efflux by drug resistance pumps. Surmounting such limitations via incorporation of OLM into self-nanoemulsifying drug delivery systems (SNEDDS). Based on OLM-equilibrium solubility studies in various oils, surfactants and co-surfactants, Capmul® MCM, Tween® 20, Cremophor® EL and polyethylene glycol - 400 (PEG) were combined in different ratios to plot ternary phase diagrams. OLM-loaded SENDDS were developed and evaluated forparticle size, polydispersity index (PDI), zeta potential, self-emulsification time, morphology, drug released percentages after 5-min (Q5min%), 1 hour (Q1h%) and dissolution efficiency percentages (DE1h%). The OL pharmacokinetics from SNEDDS (F6) and Benicar® tablets were evaluated (LC-MS/MS) in rabbits. Spherical OLM-loaded SNEDDS were developed. The best-achieved SNEDDS (F6) showed short emulsification time (13 s), fine droplet size (60.00nm), low PDI (0.25), negative zeta potential (-14.4mV), promising dissolution parameters; Q5min% (29.78%), Q1h% (66.69%) and DE1h% (47.96%) and enhanced in vivo absorption characteristics; shorter Tmax, higher Cmax and larger AUC(0−48h; suggesting its potential for the enhancement of the oral absorption of practically insoluble drugs; like OLM.

Download PDF
Proniosomes as Nano-Carrier for Transdermal Delivery of Atenolol Niosomal Gel

Mona Ebrahim Abdel Tawab Ahmed Elassal

Mona Ibrahim Abdel Tawab Ahmed El-Assal

01/12/2017

Objective of the study is to prepare Proniosomes that refers to a flexible vesicular carrier with the potential for drug administration through the transdermal route. Medthod: Proniosomes were prepared by the coacevation-phase separation technique The prepared formulations were evaluated for vesicle size, entrapment efficiency. The optimal poniosomes formula (A8) was prepared with different aqueous phase, incorporated in a gel base and studied for pH, viscosity, spredapility, stability, in vitro drug release and ex vivo permeation. Results: Niosomes formulations prepared with Span 40 and 60 have spherical and smaller Nano size. 25 mg atenolol loading has resulted 190.9 ± 15.033 nm sizes. EE% of the optimum formula prepared with distilled water was 62.11 to 92.38 .Rheological behavior showed combined shear thinning and thixotropic and gel was spreadable . Tested formulations were stable on cooling (4-8 oC) . In vitro drug release followed zero order kinetic, and gave sustained release. Release rate was significantly higher across cellulose membrane compared with rate skin. Amount of drug obtained after skin extraction was 92.6 ± 0.5% indicate enhanced permeation rate. Conclusion: All the proniosomal gel formulations were found through the acceptable range of vascular size and entrapment efficiency. Formulation A8 has been selected as an optimized therapeutic system of atenolol.

Download PDF
Olmesartan medoxomil-loaded mixed micelles: Preparation,

Mona Ebrahim Abdel Tawab Ahmed Elassal

Mohamed A. El-Gendy a, Mona I.A. El-Assal a, *, Mina Ibrahim Tadros b,

01/12/2017

Olmesartan medoxomil (OLM) is highly lipophilic in nature (log p ¼ 4.31) which attributes to its low aqueous solubility contributing to its low bioavailability 25.6%. OLM was loaded into mixed micelles carriers in a trial to enhance its solubility, thus improving its oral bioavailability. OLM-loaded mixed micelles were prepared, using a Pluronic® mixture of F127 and P123, adopting the thin-film hydration method. Three drug: Pluronic® mixture ratios (1:40, 1:50and 1: 60) and various F127: P123 ratios were prepared. OLM Loaded mixed micelles showed stability up to 12 h. The particle size of the systems varied from 364.00 nm (F3) to 13.73 nm (F18) with accepted Poly dispersity index (PDI) values. The in-vitro release studies of OLM from mixed micelles versus drug aqueous suspension were assessed using the reverse dialysis technique in a USP Dissolution tester apparatus (type II). The highest RE% (43%) was achieved with OLM-loaded mixed micelles (F8) when compared to (35%) of drug suspension. © 2017 Future University. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license

Download PDF
FORMULATION, CHARACTERIZATION AND IN VIVO APPLICATION OF ORAL INSULIN

Mona Ebrahim Abdel Tawab Ahmed Elassal

Mona El Assal, Mohamed Kassem, Amir Ali, Ali Elbadrawy

01/11/2017

The overall objective of this research is to improve the oral bioavailability of insulin through encapsulation in nanoparticles formulated by "ionotropic pre-gelation followed by polyelectrolyte complexation technique". The preparation variables such as initial drug concentration, polymer: polymer ratios, crosslinker concentration, stirring speed, stirring time, pH of drug / polymer mixture were investigated to study the effect of variables on nanoparticles size and drug entrapment efficiency. The optimum formula of insulin loaded nanoparticles was tested for insulin release in different pH media. The pharmacological activity of insulin loaded nanoparticles was evaluated following oral dosage in diabetic rats and then study whether insulin loaded nanoparticles would induce hypoglycemic effect after oral administration to diabetic rats. The optimum formula of nanoparticles improved insulin release characteristics. Thus, the polymer matrix provided protection for insulin in acidic gastric medium and allowed prolonged insulin release in alkaline intestinal medium. In vivo results indicated that nanoparticles kept insulin bioactivity and its hypoglycemic effect after oral administration of insulin loaded nanoparticles to diabetic rat model. It was found that natural biodegradable nanoparticles are a promising device for oral insulin delivery.

Download PDF
Effect of Tinidazole on Norfloxacin Disposition

Mona Ebrahim Abdel Tawab Ahmed Elassal

Mona Ibrahim Abdel tawab ElAssal and sally Ali Helmy

01/11/2017

Co-administration of norfloxacin (NFX) and tinidazole (TNZ) has been used for the treatment of gastrointestinal and urinary tract infections. Concomitant oral administration of NFX with TNZ may affect NFX absorption and consequently its blood concentration and pharmacological effect. The present study was undertaken to investigate the effect of TNZ at the usual clinical dosage on the pharmacokinetics of NFX in healthy volunteers. This study was conducted as an open-label, randomized, two-way crossover experimental design. After an overnight fast, subjects were randomized to receive a single oral dose of NFX 400 mg alone and the fixed-dose combination (FDC) of NFX /TNZ 400 mg/600mg on two different occasions separated by 1 week washout period between treatments. Blood samples were collected up to 24 h postdose, and plasma was analyzed for NFX concentrations by using HPLC. The pharmacokinetic properties of NFX after FDC administration were compared with NFX administered alone. Twelve healthy subjects were enrolled (6 in each part), and all subjects completed the study. None of the participants showed any sign of adverse drug reactions during or after the completion of the study. The 90% confidence interval (CI) between NFX alone and when co-administered with TNZ indicated the presence of an interaction between NFX and TNZ, which would significantly increase the systemic rate and exposure of NFX absorption. The co-administration of TNZ with NFX increased the AUC and Cmax of NFX significantly compared with administration of NFX alone. The AUC and Cmax of NFX alone were 6.0 μg.hr/ mL (2.3-9.8) and 0.87 μg/mL (0.4-1.6), respectively whereas the corresponding AUC and Cmax values after administration of FDC were 7.1 μg.hr/mL (4.0-10.6) and 0.97 μg/mL (0.4-1.7), respectively. The respective geometric mean ratios of NFX for AUC and Cmax with TNZ were 1.197 [90% CI, 0.941-1.522] and 1.087 (90% CI, 0.807 -1.463) compared with NFX alone. Both Tmax and Ka of NFX showed a significant decrease after administration of the combination compared to administration of NFX alone. The peak plasma concentration reached at 1.3 h (0.6-2.4) and 1.9 h (0.4-4.4) after oral administration of FDC and NFX alone, respectively. Both NFX and TNZ were well tolerated. The interaction of TNZ with fluroquinolones should be investigated to determine whether this interaction is limited to NFX or if other fluroquinolones have the same pharmacokinetic interactions. Further studies are necessary to determine the role of P-gp and other transporters on NFX disposition and pharmacokinetics. Additionally, the influence of TNZ on the physiological activity of GIT should be investigated.

Download PDF
Olmesartan Medoxomil-Loaded Self-Nanoemulsifying Drug Delivery Systems: Design, In-Vitro Characterization, and Pharmacokinetic Assessments in Rabbits Via LC-MS/MS

Mona Ebrahim Abdel Tawab Ahmed Elassal

El-Assal M I A1*, El-Gendy M A1, Tadros M I2, El-Gazayerly O N2

01/09/2017

Olmesartan medoxomil (OLM) is a lipophilic (log P = 4.31) antihypertensive drug suffering from limited oral bioavailability in humans (26%) due to its low aqueous solubility, uncontrolled enzymatic conversion to the active metabolite (olmesartan; OL) and efflux by drug resistance pumps. Surmounting such limitations via incorporation of OLM into self-nanoemulsifying drug delivery systems (SNEDDS). Based on OLM-equilibrium solubility studies in various oils, surfactants and co-surfactants, Capmul® MCM, Tween® 20, Cremophor® EL and polyethylene glycol-400 (PEG) were combined in different ratios to plot ternary phase diagrams. OLM-loaded SENDDS were developed and evaluated for particle size, polydispersity index (PDI), zeta potential, self-emulsification time, morphology, drug released percentages after 5-min (Q5min%), 1-hour (Q1h%) and dissolution efficiency percentages (DE1h%). The OL pharmacokinetics from SNEDDS (F6) and Benicar® tablets were evaluated (LC-MS/MS) in rabbits. Spherical OLM-loaded SNEDDS were developed. The best-achieved SNEDDS (F6) showed short emulsification time (13 s), fine droplet size (60.00 nm), low PDI (0.25), negative zeta potential (-14.4 mV), promising dissolution parameters; Q5min% (29.78%), Q1h% (66.69%) and DE1h% (47.96%) and enhanced in vivo absorption characteristics; shorter Tmax, higher Cmax and larger AUC(0−48h; suggesting its potential for the enhancement of the oral absorption of practically insoluble drugs; like OLM.

Download PDF
ACYCLOVIR – LOADED SOLID LIPID NANOPARTICLE BASED CREAM: A NOVEL

Mona Ebrahim Abdel Tawab Ahmed Elassal

Mona Ibrahim Abdel Tawab El-assal

01/03/2017

Background Topical treatment of skin diseases needs to be strategic to ensure high drug concentration in the skin with minimum systemic absorption. The present investigation was enthused by the possibility to develop solid lipid nanoparticles (SLNs) of hydrophilic drug acyclovir. Also study vitro and vivo drug delivery. Methods: Acyclovir loaded solid lipid nanoparticles were prepared by high pressure homogenization of aqueous surfactant solutions containing the drug-loaded lipids in the melted or in the solid state with formula optimization study. Acyclovir loaded solid lipid nanoparticles were incorporated in cream base. The pH was evaluated and rheological study. Drug release was evaluated and compared with drug based on simple cream. Also the release of acyclovir loaded solid lipid nanoparticles conjugate with compritol 888ATO was compared with marketed cream. The potential of solid lipid as the carrier for dermal delivery was studied. Results: Particle size analysis of SLNs prove small, smooth, spherical shape particle ranged from 150 to 200 nm for unloaded and from 330 to 444 nm for acyclovir loaded particles. The EE% for optimal formula is 72% with suitable pH for skin application. Rheological behavior is shear thinning and thixotropic. Release study proved controlled drug release especially in formula containing compritol88 ATO. Stability study emphasized an insignificant change in the particles properties over 6 month. Invivo study showed significantly higher accumulation of acyclovir in stratum corneum compared with blank skin. Conclusion: acyclovir loaded solid lipid nanoparticles might be beneficial in controlling drug release, stable and improving dermal delivery of antiviral agent(s)

Download PDF
Formulation, Optimization, and Evaluation of Solid Dispersions of metformin HCl Using Factorial Design

Mona Ebrahim Abdel Tawab Ahmed Elassal

Mona El Assal, Mohammed mannaa, Ahmed Abdel Bary,

01/12/2016

ABSTRACT The objective of this study is to achieve the controlling dissolution rate of Metformin HCl, a freely water soluble antidiabetic drug. Solid dispersions microcapsules were prepared using solvent evaporation method which enclosed preparation of a uniform dispersion of Metformin HCl in (Hydroxy propyl methylcellulose k100, Ethyl cellulose, Eudragit RL PO, RS PO & Compritol 888 ATO). A two-factor, General factorial statistical design was used to quantitate the effect of polymer type (X1) and drug: polymer ratio(X2) on the release profile. Where polymer type and drug: polymer ratio were selected as independent variables, while Y1 (cumulative drug release after 1 hr. ) and Y2 (cumulative drug release in 3 hrs. ), Y3 (cumulative drug release in 10 hrs.),Y4 (angle of repose ) and Y5 (Hausner ratio) were selected as dependent variables. The solid dispersions were characterized for their in vitro- release rate. The optimized formulation was further characterized by Drug scanning calorimetry, infrared spectrophotometry, X-Ray Diffractometer and SEM analysis. A convenient statistical model was made and a significantly controlled release rate was exhibited .the optimized formulation was investigated by DSC, XRD, FTIR and SEM data which showed the crystalline nature of Metformin HCl in a solid dispersion, the statistical model helped us to recognize the effects of formulation variables on the dispersion. Keywords: Metformin HCl, Solid dispersion, controlled release, factorial design, HPMC k 100, Ethyl cellulose, Eudragit RL, RS& Compritol ATO 888.

Download PDF
Gelatine Based Nanoparticles as Drug Delivery System of Lornoxicam Gel

Mona Ebrahim Abdel Tawab Ahmed Elassal

01/10/2016

Abstract: The purpose of contemporary study was to project GNP by using of two step desolvation method. Biodegradable hydrophilic gelatin nanoparticles used as a delivery system of anti-inflammatory lornoxicam after gel formulation using each of hydroxyl propyl methyl cellulose (HPMC) and carbopol as gelling agent. The size and shape of the nanoparticles were examined by optical microscope and transmission electron microscopy, particles with a mean diameter of 240.6 nm and 0.1 poly dispersibility index PDI were produced and the percentage of entrapment efficiency was found to be 87.1%. The optimum amount of LOR loading was obtained. Four formulas were prepared F1 standard LOR carbopol gel, F2 standard LOR HPMC gel, F3 GNP –LOR containing carbopol as gelling agent and F4 GNP –LOR which has HPMC as gelling agent are GNP-LOR gel. Permeation of drug through membrane was determined by Franz diffusion cell. Further stability studies were carried out at 4Co for a period of 8 weeks. Vivo study was carried on white albino male rats to compare between different lornoxicam gel formulations. Conclusion: Results show that the two step desolvation is an appropriate method for preparing GNP. LORF3 which has carbopol as gelling agent was of lower release rate with maximum % inhibition of edema.

Download PDF
Single dose Linezolid Pharmacokinetics in ill Patienys with Impaired Renal Function Epecially Chronic Hemodialysis Patients

Mona Ebrahim Abdel Tawab Ahmed Elassal

01/01/2014

ABSTRACT: Background and Objective: Renal failure patients were treated with linezolid (LZD) for proven or suspected infections by multi-resistant Gram-positive cocci. The aim of this study was to determine if dose adjustment of LZD is needed as a function of renal impairment or not, especially that a significant component of LZD is eliminated unchanged in urine. Methods: The single dose pharmacokinetics of LZD was investigated. Eighteen non-infected male subjects with various degrees of renal impairment ranged from normal to severe chronic impairment were enrolled, including end-stage renal disease (ESRD) patients maintained on hemodialysis (HD). LZD was administered as a single oral 600mg dose, and blood samples were drawn at different times and analysed by a validated HPLC assay method. Plasma profiles were evaluated by non-compartmental and compartmental approaches. Results and Discussion: A similar rate and extent of LZD absorption and elimination and comparable body exposure was observed in both healthy subjects and acute renal failure patients. The extent of LZD exposure was significantly increased by 3-fold in ESRD patients in their off-dialysis day. Furthermore, the t1/2 and MRT values were significantly increased by ~5- and 3-fold, respectively. The Vd/F values of LZD did not change with renal function. A significant decrease in CL/F by ~3-fold was observed in ESRD patients in their off-dialysis day however, CL/F was significantly increased by ~4-fold during HD. Approximately half of the administered LZD dose was removed during the HD session in these selected cohorts of ESRD patients. LZD was generally well tolerated. Conclusions: The dose of LZD did not need to be adjusted for patients with acute renal dysfunction or ESRD on HD. One of the twice-daily doses should be administered after the dialysis session because almost half of the LZD dose was substantially removed by HD. During the first three dialysis sessions of the treatment course, to avoid potentially ineffective therapy, a supplemental dose of LZD might be given if necessary or the dose of LZD should be administered 4 h before the beginning of the HD session. This was to keep LZD levels above the MIC for the organism causing the infection being treated.

Download PDF
Nanoparticles Improved Drug Radio Protective Activity

Mona Ebrahim Abdel Tawab Ahmed Elassal

01/01/2013

Radio protective agents are synthetic compounds or natural products that are immediately administrated before irradiation to reduce injuries caused by ionizing radiation. Toxicity, short duration, and the unfavorable routes of administration, have prevented the widespread use of most radio protective agents in practice. This study aimed to evaluate the use of slowly release-long circulation biodegradable polymer Poly (lactide-co-glycolide) (PLGA) as carrier for certain water soluble radio protective agents. Penicillamine and Potassium lodide (KI) were selected as examples radio protectors which can be used to protect against both internal radionuclide (chronic radiation exposure) and external beam irradiation (acute radiation exposure). Emulsion-solvent evaporation method (ESE) was used to prepare hydrophilic-drug loaded PLGA Nanoparticles (PLGA-NPs) is an efficient and reproducible manner. Results revealed that single oral administration of Penicillamine-NPs or KI-NPs was effective as free drug (for 5 successive days) which indicate that PLGA-NPs could be used to modulate radio protective drug activity in biological system, and to improve drug efficacy in different body organs for longer duration than the equal dose of free drug.

Download PDF
Role of Natural Biodegradable Microspheres to Improve Bioavailability of Certain Anti-Anemic Drugs in Rat

Mona Ebrahim Abdel Tawab Ahmed Elassal

01/01/2013

Iron deficiency anemia, the second most common cause of anemia in the elderly, usually results from chronic gastrointestinal (GI) blood loss. One of the most attractive areas of research in drug delivery today is the design of micro particulate systems (microspheres) that are able to deliver drugs to the right place, at appropriate times and at the right dosage. The ability of natural biodegradable polymers as (sodium alginate and sodium carboxymethyl cellulose) to swell and regulate the release of encapsulated certain anti anemic drugs such as (ferrous sulphate and ferrous fumarate) by controlling crosslinking makes them attractive as materials in the controlled release of drugs. The rat iron repletion test was subsequently adapted as the standard method of analysis for the availability of iron.

Download PDF
Preparation and Evaluation of Certain Hydrophilic drug Loaded Microspheres

Mona Ebrahim Abdel Tawab Ahmed Elassal

01/01/2012

Preparation and Evaluation of Certain Hydrophilic drug Loaded Microspheres

Download PDF
Preparation and Evaluation of Certain Hydrophilic drug Loaded Microspheres.

Mona Ebrahim Abdel Tawab Ahmed Elassal

Mohamed Aly Kassem and Aly Al-Saeed Al-Badrawy

01/01/2012

Download PDF
Pharmacokinetic of Fluconazole Antifungal Drug in Patients on Maintenance Haemodialysis

Mona Ebrahim Abdel Tawab Ahmed Elassal

01/01/2010

Pharmacokinetic of Fluconazole Antifungal Drug in Patients on Maintenance Haemodialysis

Download PDF
Outcome of Intermittent Doses of Simvastatin in Hemodialysis Patients with Low LDL Cholesterol Levels

Mona Ebrahim Abdel Tawab Ahmed Elassal

01/01/2010

Outcome of Intermittent Doses of Simvastatin in Hemodialysis Patients with Low LDL Cholesterol Levels

Download PDF

Awards

Award Donor Date
Certificate of Excellence Meletary Medical Services 2005

Follow us on

Visit the Faculty

ADS